-0.150 (-2.42%)
Range 6.000 - 6.340   (5.67%)
Open 6.250
Previous Close 6.190
Buy Price 6.000
Buy Volume 9
Sell Price 6.120
Sell Volume 14
Volume 196,278
Value -
Measurement Type Value
EPS (USD) -0.764
Trailing EPS (USD) -
NAV (USD) 4.481
Cash In Hand (USD) 1.055
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 1.422
Price / Cash In Hand 6.038
Issued & Paid-up Shares 129,739,000
Treasury Shares 700,000
Market Cap (M) 826.437
Par Value (USD) n.a.
Beta - 75 Days 1.488
R-Squared - 75 Days(%) 12.4
Beta - 500 Days 1.5
R-Squared - 500 Days(%) 8.29
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 30 Nov 2021 05:00.
Data powered by
View All Events


Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates, which represents its lead programs where it focuses on time and resources, such as MPC-06-ID, MPC-150-IM, JR-031, MPC-300-IV and MSC-100-IV, and tier 2 product candidates, which advances to tier 1 depending on newly-generated data, market opportunity or partnering options, such as MSC-100-IV, MPC-25-IC, MPC-25-Osteo and MPC-CBE.

Loading Chart...